AU2016225133B2 - Substituted nucleoside derivatives useful as anticancer agents - Google Patents

Substituted nucleoside derivatives useful as anticancer agents Download PDF

Info

Publication number
AU2016225133B2
AU2016225133B2 AU2016225133A AU2016225133A AU2016225133B2 AU 2016225133 B2 AU2016225133 B2 AU 2016225133B2 AU 2016225133 A AU2016225133 A AU 2016225133A AU 2016225133 A AU2016225133 A AU 2016225133A AU 2016225133 B2 AU2016225133 B2 AU 2016225133B2
Authority
AU
Australia
Prior art keywords
cancer
mmol
compound
etoac
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016225133A
Other languages
English (en)
Other versions
AU2016225133A1 (en
Inventor
Robert Arnold Kumpf
Indrawan James Mcalpine
Michele Ann Mctigue
Eugene Yuanjin Rui
John Howard Tatlock
Michelle Bich Tran-Dube
Martin James Wythes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2016225133A1 publication Critical patent/AU2016225133A1/en
Application granted granted Critical
Publication of AU2016225133B2 publication Critical patent/AU2016225133B2/en
Priority to AU2018278842A priority Critical patent/AU2018278842A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
AU2016225133A 2015-02-24 2016-02-15 Substituted nucleoside derivatives useful as anticancer agents Ceased AU2016225133B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018278842A AU2018278842A1 (en) 2015-02-24 2018-12-11 Substituted nucleoside derivatives useful as anticancer agents

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562119932P 2015-02-24 2015-02-24
US62/119,932 2015-02-24
US201562213801P 2015-09-03 2015-09-03
US62/213,801 2015-09-03
US201662279209P 2016-01-15 2016-01-15
US62/279,209 2016-01-15
PCT/IB2016/050803 WO2016135582A1 (en) 2015-02-24 2016-02-15 Substituted nucleoside derivatives useful as anticancer agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018278842A Division AU2018278842A1 (en) 2015-02-24 2018-12-11 Substituted nucleoside derivatives useful as anticancer agents

Publications (2)

Publication Number Publication Date
AU2016225133A1 AU2016225133A1 (en) 2017-08-10
AU2016225133B2 true AU2016225133B2 (en) 2018-11-29

Family

ID=55451515

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016225133A Ceased AU2016225133B2 (en) 2015-02-24 2016-02-15 Substituted nucleoside derivatives useful as anticancer agents
AU2018278842A Abandoned AU2018278842A1 (en) 2015-02-24 2018-12-11 Substituted nucleoside derivatives useful as anticancer agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018278842A Abandoned AU2018278842A1 (en) 2015-02-24 2018-12-11 Substituted nucleoside derivatives useful as anticancer agents

Country Status (29)

Country Link
US (1) US10428104B2 (cg-RX-API-DMAC7.html)
EP (1) EP3262057B1 (cg-RX-API-DMAC7.html)
JP (1) JP6584521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170119705A (cg-RX-API-DMAC7.html)
CN (1) CN107278205A (cg-RX-API-DMAC7.html)
AU (2) AU2016225133B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017017396A2 (cg-RX-API-DMAC7.html)
CA (1) CA2921314A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002155A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017008403A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170384A (cg-RX-API-DMAC7.html)
CU (1) CU20170105A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000195A (cg-RX-API-DMAC7.html)
EA (1) EA031895B1 (cg-RX-API-DMAC7.html)
ES (1) ES2792899T3 (cg-RX-API-DMAC7.html)
GT (1) GT201700189A (cg-RX-API-DMAC7.html)
IL (1) IL253637A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017010844A (cg-RX-API-DMAC7.html)
NI (1) NI201700095A (cg-RX-API-DMAC7.html)
PE (1) PE20171449A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501413A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201706050WA (cg-RX-API-DMAC7.html)
SV (1) SV2017005514A (cg-RX-API-DMAC7.html)
TN (1) TN2017000357A1 (cg-RX-API-DMAC7.html)
TW (1) TWI622595B (cg-RX-API-DMAC7.html)
UA (1) UA118315C2 (cg-RX-API-DMAC7.html)
UY (1) UY36564A (cg-RX-API-DMAC7.html)
WO (1) WO2016135582A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201705092B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
ES2891320T3 (es) 2016-03-10 2022-01-27 Janssen Pharmaceutica Nv Análogos de nucleósidos sustituidos para su uso como inhibidores de PRMT5
KR20180116307A (ko) 2016-03-10 2018-10-24 얀센 파마슈티카 엔.브이. Prmt5 저해제로 사용하기 위한 치환 뉴클레오사이드 유사체
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
MX392051B (es) 2016-09-14 2025-03-21 Janssen Pharmaceutica Nv Inhibidores espirobiciclicos de la interaccion de menina-mll
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
KR102531344B1 (ko) * 2016-10-03 2023-05-10 얀센 파마슈티카 엔.브이. Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のアゼパン阻害剤
WO2018152501A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US11220524B2 (en) * 2017-02-20 2022-01-11 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ.ベー. Prmt5阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
BR112020002736A2 (pt) 2017-08-09 2020-07-28 Prelude Therapeutics, Incorporated inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
CA3079545A1 (en) 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP7352544B2 (ja) 2017-12-08 2023-09-28 ヤンセン ファーマシューティカ エヌ.ベー. 新規なスピロ二環式類似体
AU2018385664B2 (en) 2017-12-13 2022-06-02 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CA3092357A1 (en) * 2018-03-14 2019-09-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20220160713A1 (en) * 2019-02-13 2022-05-26 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
JP7609798B2 (ja) * 2019-03-25 2025-01-07 カリフォルニア インスティチュート オブ テクノロジー Prmt5インヒビター及びその使用
WO2020206299A1 (en) 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法
DK3980417T3 (en) 2019-06-10 2023-12-18 Lupin Ltd PRMT5-Inhibitorer
PE20220433A1 (es) 2019-06-12 2022-03-29 Janssen Pharmaceutica Nv Intermedios espirobiciclicos novedosos
RS64931B9 (sr) 2019-06-18 2025-06-30 Pfizer Derivati benzizoxazol sulfonamida
BR112022004630A2 (pt) * 2019-09-18 2022-05-31 Prelude Therapeutics Inc Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
BR112022007808A2 (pt) 2019-10-22 2022-07-05 Lupin Ltd Combinação farmacêutica de inibidores de prmt5
JP7664248B2 (ja) 2019-12-03 2025-04-17 ルピン・リミテッド Prmt5阻害剤としての置換ヌクレオシドアナログ
UA129208C2 (uk) 2019-12-19 2025-02-05 Янссен Фармацевтика Нв Заміщені спіропохідні з прямим ланцюгом
CA3192055A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
KR20230096973A (ko) 2020-08-18 2023-06-30 인사이트 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간체
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
WO2023017152A1 (en) * 2021-08-13 2023-02-16 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7022681B2 (en) * 2002-08-15 2006-04-04 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
EP2408306A4 (en) * 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
EP2731434A4 (en) * 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
US8575119B2 (en) * 2011-09-23 2013-11-05 Enanta Pharmaceuticals, Inc. 2′-chloroacetylenyl substituted nucleoside derivatives
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
JP2018523665A (ja) * 2015-08-06 2018-08-23 キメリックス インコーポレイテッド 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体

Also Published As

Publication number Publication date
JP6584521B2 (ja) 2019-10-02
EP3262057B1 (en) 2020-04-15
TWI622595B (zh) 2018-05-01
CR20170384A (es) 2017-11-16
US10428104B2 (en) 2019-10-01
UY36564A (es) 2016-09-30
ZA201705092B (en) 2019-06-26
TN2017000357A1 (en) 2019-01-16
CU20170105A7 (es) 2017-10-05
KR20170119705A (ko) 2017-10-27
US20160244475A1 (en) 2016-08-25
GT201700189A (es) 2019-06-10
CN107278205A (zh) 2017-10-20
BR112017017396A2 (pt) 2018-04-03
SG11201706050WA (en) 2017-09-28
AU2016225133A1 (en) 2017-08-10
AU2018278842A1 (en) 2019-01-03
DOP2017000195A (es) 2017-10-15
UA118315C2 (uk) 2018-12-26
CL2017002155A1 (es) 2018-05-11
PE20171449A1 (es) 2017-10-02
EA031895B1 (ru) 2019-03-29
MX2017010844A (es) 2017-12-07
CA2921314A1 (en) 2016-08-24
CO2017008403A2 (es) 2017-10-31
ES2792899T3 (es) 2020-11-12
TW201643176A (zh) 2016-12-16
EP3262057A1 (en) 2018-01-03
IL253637A0 (en) 2017-09-28
PH12017501413A1 (en) 2018-01-29
NI201700095A (es) 2017-10-31
WO2016135582A1 (en) 2016-09-01
SV2017005514A (es) 2018-04-11
EA201791563A1 (ru) 2018-01-31
JP2018510850A (ja) 2018-04-19

Similar Documents

Publication Publication Date Title
AU2016225133B2 (en) Substituted nucleoside derivatives useful as anticancer agents
US10709709B2 (en) Substituted carbonucleoside derivatives useful as anticancer agents
OA18433A (en) Substituted nucleoside derivatives useful as anticancer agents
HK1241886A1 (en) Substituted nucleoside derivatives useful as anticancer agents
NZ748652B2 (en) Substituted carbonucleoside derivatives useful as anticancer agents
HK40008995A (en) Substituted carbonucleoside derivatives useful as anticancer agents
OA19125A (en) Substituted carbonucleoside derivatives useful as anticancer agents
HK40008995B (en) Substituted carbonucleoside derivatives useful as anticancer agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired